Sonnet BioTherapeutics Holdings, Inc. announced that the SB221 study of SON-1010 (recombinant human Interleukin-12 linked to Sonnet's fully-human albumin binding domain or IL12-FHAB) dosed in combination with atezolizumab (Tecentriq) will be presented as a 'Trial in Progress' poster at ASCO 2024. Study SB221 (NCT05756907) is a Phase 1b/2a multicenter, dose-escalation, and proof-of-concept clinical study to assess the safety, tolerability, PK, PD, and efficacy of SON-1010 administered SC, either alone or in combination with a fixed dose of atezolizumab given IV. The work will be presented in a poster session at the upcoming American Society of Clinical Oncology Annual Meeting 2024, to be held May 31 to June 4 in Chicago, Illinois.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9 USD | -1.10% | -3.23% | -48.28% |
Jul. 05 | Sonnet BioTherapeutics Files Registration for Sale of Up to 5.77 Million Shares by Selling Stockholders | MT |
Jun. 20 | Top Midday Decliners | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.28% | 2.8M | |
+57.48% | 827B | |
-7.18% | 350B | |
+15.37% | 319B | |
+7.45% | 294B | |
+13.62% | 240B | |
+14.55% | 221B | |
-0.33% | 219B | |
+8.14% | 167B | |
-2.99% | 158B |
- Stock Market
- Equities
- SONN Stock
- News Sonnet BioTherapeutics Holdings, Inc.
- Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting